Table 4.

General non-hematologic dose modifications for poly (ADP-ribose) polymerase inhibitor (PARPi) treatment

Severity	Management
Grade 1	Continue treatment Consider dose interruptions or reductions if considered clinically intolerable by the patient, despite adequate symptom management
Grade 2	Continue treatment Consider dose interruptions or reductions if it does not improve with symptom management, or if considered clinically intolerable by the patient
Grade≥3 where prophylaxis is not feasible or AE persists despite treatment	Withhold for a maximum of 28 days or until resolution of adverse reaction; then, consider dose reduction.
Grade ≥3 lasting >28 days on the lowest dose-level	If AE persists despite adequate management, permanently discontinue medication

AE, adverse event.